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Biochemical and morphological alterations of mitochondria may play an important role in the pathogenesis of Alzheimer’s
disease (AD). Particularly, mitochondrial dysfunction is a hallmark of amyloid-beta-induced neuronal toxicity in Alzheimer’s
disease. The recent emphasis on the intracellular biology of amyloid-beta and its precursor protein (APP) has led researchers
to consider the possibility that mitochondria-associated and mitochondrial amyloid-beta may directly cause neurotoxicity. Both
proteins are known to localize to mitochondrial membranes, block the transport of nuclear-encoded mitochondrial proteins
to mitochondria, interact with mitochondrial proteins, disrupt the electron transport chain, increase reactive oxygen species
production, cause mitochondrial damage, and prevent neurons from functioning normally. In this paper, we will outline current
knowledge of the intracellular localization of amyloid-beta. Moreover, we summarize evidence from AD postmortem brain as
well as animal AD models showing that amyloid-beta triggers mitochondrial dysfunction through a number of pathways such as
impairment of oxidative phosphorylation, elevation of reactive oxygen species production, alteration of mitochondrial dynamics,
and interaction with mitochondrial proteins. Thus, this paper supports the Alzheimer cascade mitochondrial hypothesis such as
the most important early events in this disease, and probably one of the future strategies on the therapy of this neurodegenerative
disease.
1.Introduction
Each year, over 10 million people globally suﬀer from neuro-
degenerative diseases. This ﬁgure is expected to grow by
20% over the next decade as the aging population increases
and lives longer. This disease group is the fourth biggest
killer in the developed world after heart diseases, cancer, and
stroke[1].Themostcommonneurodegenerativediseasesare
AD, Parkinson disease, Lewy body dementia, frontotemporal
dementia, and amyotrophic lateral sclerosis [2]. The most
widely recognized is AD, which is among the principal
debilitatingconditionsofthecurrentcentury.Approximately
24 million people worldwide suﬀer from dementia, 60% of
cases being due to AD, which occurs in 1% of individuals
aged 50 to 70 years old and dramatically increases to 50% of
those over 70 years old [3]. Dramatically, these numbers are
estimated to increase to 15 million in the next 40 years [4].
From the neuropathological point of view, AD is char-
acterized by selective neuronal loss, marked synaptic alter-
ation, morphological mitochondrial abnormalities, and Tau
pathology. The histological hallmark lesions of AD are
characterized by senile plaques and cerebrovascular deposits.
The extracellular amyloid plaques mainly composed of
amyloid-beta and intracellular neuroﬁbrillary tangles built
up of hyperphosphorylated tau, although the molecular
mechanisms underlying the disease are still unknown and
there is still no cure. Many lines of evidence suggest that
oxidative stress is one of the earliest changes and plays an
important role in the pathological process in AD, and more
recently, energy deﬁciency and mitochondrial dysfunction
have been recognized as a prominent, early event in AD [1–
11]. Oxidative stress plays a critical role in the pathogenesis
of AD and is intimately linked to aging, the best established
risk factor for AD. Increased oxidative stress levels have been
found in the brains of patients with AD in Sweden and
early in Tg2576 APP transgenic mice [12, 13]. Recently, we
described that PLA2G3 gene silencing produced a marked
inhibition of the free radical-generating xanthine/xanthine
oxidase- (X-XOD-) system-induced cell death, and that
PLA2G3polymorphismsareassociatedwithADinaSpanish
case-control sample [14]. In previous studies with choroid
plexus homogenates with diﬀerent cases with AD in the2 Journal of Aging Research
diﬀerent stages (I/0, III-IV, and V-VI), we demonstrated that
in AD patients, amyloid-beta peptide also accumulates in
choroid plexus [15], there is an oxidation of carboxymethyl-
lysine (CML), and N-carboxyethyl-lysine (CEL) may result
in impaired protein interactions, protein folding, and pro-
tein kinase activity; abnormal function of endothelial and
vascular smooth muscle cells; impaired HDL-cholesterol
metabolism in the choroid plexus in advanced stages of AD
[16].
2. Mitochondria
Mitochondria are found in virtually all eukaryotic cells and
function to generate cellular energy in the form of adenosine
triphosphate (ATP) by oxidative phosphorylation and are
thought to be derived evolutionarily from the fusion of
prokaryotic and eukaryotic organisms [17]. They are also
involved in regulation of cell death via apoptosis, in the
control of cell division and growth, in calcium homeostasis,
haem biosynthesis, and in the formation and export of iron-
sulphur clusters.
Mitochondria are composed of a double lipid mem-
brane which structures four compartments, distinct by
composition and function (Figure 1). The porous outer
membrane encompasses the whole organelle. It contains
many proteins like import complexes and voltage-dependent
anion channels responsible for the free passage of low-
molecular-weight substances (up to 5000Da) between the
cytoplasm and the intermembrane space which represents
a reservoir of protons establishing a proton electrochemical
gradient across inner mitochondrial membrane that is
needed for the production of ATP via ATPase (complex
V). Intermembrane space contains proapoptotic proteins
like cytochrome c, Smac/Diablo, EndoG, and Htra2/Omi.
In contrast to the permeable outer membrane, the inner
mitochondrial membrane, rich in cardiolipin, provides a
highly eﬃcient barrier to the ﬂow of small molecules and
ions, including protons. This membrane is invaginated into
numerous cristae increasing cell surface area. It houses the
respiratory enzymes of the electron transport chain, the
cofactor coenzyme Q, and many mitochondrial carriers. In
thematrix,diﬀerentmetabolicpathwaystakeplaceincluding
the tricarboxylic or Krebs cycle [18].
Mitochondria are unique amongst cellular organelles in
that they have their own, circular, double-stranded DNA
(mtDNA) which is inherited almost exclusively down the
maternal line and codes for 37 mitochondrial genes, 13 of
which translate to proteins involved in oxidative phospho-
rylation [18, 19]. The remaining genes encode transfer
(22 genes) and ribosomal (2 genes) RNA allowing the
mitochondria to generate their own proteins. Although
mitochondria have the ability to produce proteins, the vast
majority of proteins that function within the mitochondria,
including those involved in DNA transcription, translation,
and repair, are encoded by nuclear DNA and are transported
intothemitochondriafromthecytosol.AsmtDNAislocated
in the mitochondria in close proximity to the electron
Figure 1: Representative electromicrographs of mitochondrial
ultrastructure. Scale bar 200nm.
transport chain, it is more susceptible to damage from free
radicals generated during oxidative phosphorylation [20].
Mitochondriagenerateenergybytwocloselycoordinated
metabolic processes: Krebs cycle and the oxidative phospho-
rylation (OXPHOS). OXPHOS is made up of the electron
transportchainassembledinfourenzymes(complexItoIV)
as well as the F1F0-ATP synthase (complex V). Complexes
I, III, and IV are located in inner mitochondrial membrane
as integral proteins, whereas complex II is attached to the
inner surface of this membrane. The function of the chain
is to generate cellular energy in the form of ATP. These
ﬁve enzymes of the complex are connected functionally
by mobile electron acceptors and donors: ubiquinone and
cytochrome c. Electrons from NADH and FADH2 are
fed into complexes I and II, respectively. Ubiquinone Q
carries electrons from both complexes to complex II, and
cytochrome c does it from complex III to IV reducing
molecular oxygen to water. As electrons are transferred
along electron transport chain, a ﬁxed number of protons
are pumped from the matrix into inner membrane space
establishing a electrochemical gradient characterized with
a speciﬁc electrical potential. The redox energy drives the
synthesis of ATP from ADP as protons are transported back
from inner membrane space into the matrix via complex V.
3. Amyloid-Beta inthe Cytosol
Accumulation of amyloid-beta in AD brains is thought
to underlie neuronal dysfunction and memory loss, being
centrally implicated in AD pathogenesis. Moreover, previous
to mitochondrial accumulation of amyloid-beta showed in
AD patient and AD transgenic mouse brain, the toxic
amyloid-beta species has to be accumulated in the cytosol
of the cells. Many studies showed amyloid-beta interaction
with diﬀerent receptors in the cellular membrane of the
vasculature, neurons, oligodendrocytes, and glial cells where
it is transported from cell surface into endosomal and
lysosomal compartments [21–23]. The aberrant signalling of
thesereceptorsinADtriggeredanabnormalaccumulationof
amyloid-beta into cytosol-inducing cellular stress underlies
to neuronal dysfunction and dementia.Journal of Aging Research 3
It is described by our group and others that these recep-
tors can be megalin, also known as low-density lipoprotein-
related protein-2 (LRP2) [24], LRP-1 [22], or RAGE
(receptors for advanced glycation end products) [25]. The
interaction of these receptors with amyloid-beta in neurons,
microglia, and vascular cells accelerates and ampliﬁes dele-
terious eﬀects on neuronal and synaptic functions. These
ﬁndings are further in line with the recently proposed
hypothesis of an intracellular amyloid-beta toxicity cascade
which suggests that the toxic amyloid-beta species inter-
vening in molecular and biochemical abnormalities may
be intracellular soluble aggregates instead of extracellular,
insoluble plaques. There are many studies proposing that
megalin- and/or RAGE-dependent signalling are involved in
the regulation of amyloid-beta clearance and probably may
contribute to amyloid pathology and cognitive dysfunction
observed in the AD patients and AD mouse model.
4.Amyloid-Beta andMitochondria
Studies of postmortem brains from AD patients and trans-
genic mouse models of AD suggest that oxidative damage,
induced by amyloid-beta, is associated with mitochondria
early in AD progression. Amyloid-beta and APP protein
are known to localize to mitochondrial membranes, block
the transport of nuclear-encoded mitochondrial proteins to
mitochondria, interact with mitochondrial proteins, disrupt
the electron transport chain, increase reactive oxygen species
(ROS) production, cause mitochondrial damage, and pre-
vent neurons from functioning normally. Recent scientiﬁc
researchhasidentiﬁed multiple mechanisms ofamyloid-beta
interaction with mitochondria at diﬀerent mitochondrial
compartments: the outer mitochondrial membrane, inter-
membrane space, inner mitochondrial membrane, and the
matrix. It is well known that the involvement of amyloid-
beta-induced mitochondrial dysfunction in AD pathogene-
sis, a vicious cycle as well as several vicious circles within the
cycle, each accelerating the other, can be drawn emphasizing
the Alzheimer mitochondrial cascade hypothesis.
The brain is vulnerable to oxidative stress owing to its
highlipidcontent,itsrelativelyhighoxygenmetabolism,and
its low levels of antioxidant defenses [26]. One of the most
interestingeventsinADisthatmitochondrialoxidativestress
occurs early in AD progression, before the onset of amyloid-
beta pathology [27, 28]. Oxidative stress was also reported in
the mitochondria of other tissues diﬀerent to the brain such
as platelets and ﬁbroblasts from AD patients [29, 30].
Free radicals (compounds with an unpaired electron) or
ROS are a normal part of metabolism. Mitochondria are the
majorsourceofROS,and,infact,mitochondrialdysfunction
as well as hypometabolism has long been implicated in the
onset of the familial and sporadic forms of AD [31]. mtDNA
defects have also been linked to an increased incidence of AD
[32]. Quantitative morphometric, molecular, and cellular
analysis of mitochondria shows increased abnormal and
damaged mitochondria in AD [33, 34]. Energy deﬁciency
and mitochondrial dysfunction have been recognized as a
prominent, early event in AD.
Mitochondrial abnormalities have been found both in
neurons and astrocytes [35–37], suggesting that both neu-
rons and astrocytes might be damaged by free radicals in
the AD brain. Superoxide radicals might be produced in
mitochondrial electron transport chain complexes I and III
[38] and in components of the Krebs cycle, including a-
ketoglutarate dehydrogenase [39]. In addition, superoxide
radicals might be generated in the outer mitochondrial
membrane. H2O2 and superoxide radicals, released from the
mitochondrial matrix and from the inner and outer mito-
chondrial membranes, might be carried to the cytoplasm
and, ultimately, might lead to the oxidation of cytoplasmic
proteins [26].
Several lines of evidence suggest that APP and amyloid-
beta are factors contributing to mitochondrial dysfunction
in AD (Figure 2). Mitochondria were found to be the target
both for amyloid precursor protein (APP) that accumulates
in the mitochondrial import channels and for amyloid-beta
that interacts with several proteins inside mitochondria and
leads to mitochondrial dysfunction [30]. Multiple lines of
evidence support APP and amyloid-beta as contributing
factors to mitochondrial dysfunction in AD: both APP and
amyloid-beta are present in mitochondrial membrane and
interact with mitochondrial proteins, block mitochondrial
import channels, impair mitochondrial transport, disrupt
the electron transfer chain, increase ROS levels, and cause
mitochondrial damage.
With regard to localization of APP in mitochondria, it
was demonstrated that APP formed stable 480kDa com-
plexes with the translocase of the outer mitochondrial
membrane40(TOM40)importchannelandasupercomplex
of approximately 620kDa with both mitochondrial TOM40
and the translocase of the inner mitochondrial membrane
23 (TIM23) import channel TIM23 in an N (in mitochon-
dria) -C (out of cytoplasm) orientation [40]. Interestingly,
in brain tissues of AD-aﬀected subjects, APP localized with
mitochondria fraction, associated to TOM40 and TIM23, in
a translocation-arrested manner, that may prevent import of
de novo synthesised nuclear-encoded mitochondrial protein,
such as subunits of the electron transport chain [27].
In agreement with the intracellular localization of APP,
cell studies showed mitochondrial accumulation of amyloid-
beta in AD patients and APP mouse transgenic mouse brain
[28]. In transgenic APP mice, mitochondrial amyloid-beta
accumulation increased at around 4 months of age, well
before the formation of plaques [41]. In total, these ﬁndings
are further in line with the recently proposed hypothesis of
an intracellular amyloid-beta toxicity cascade which suggests
that the toxic amyloid-beta species intervening in molecular
and biochemical abnormalities may be intracellular soluble
aggregates instead of extracellular, insoluble plaques [42].
APP and amyloid-beta may block mitochondrial translo-
cationofnuclear-encodedproteins[32],suchascomponents
of the electron transport chain [43–45], impairing mito-
chondrial function. Intramitochondrial amyloid-beta is able
to perturb mitochondrial function in several ways by directly
inﬂuencing extracellular transport chain complex activities
[46], impairing mitochondrial dynamics [11], or disturbing
calcium storage [47, 48], thus increasing apoptotic pathways4 Journal of Aging Research
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Figure 2: APP processing in nondemented healthy individuals and AD patients. APP processing occurs by two pathways: a beta-
secretase-based amyloidogenic and alpha-secretase-based nonamyloidogenic pathway. In the nonamyloidogenic pathway (left), cleavage
occurs by alpha-secretase within the amyloid-beta domain and generates the large soluble N-terminal fragment (sAPPα) and a non-
amyloidogenic C-terminal fragment of 83 amino acid residues (C83). Further cleavage of this C-terminal fragment by γ-secretase generates
thenonamyloidogenicpeptide(P3)andAPPintracellulardomain(ACID).Theseproductsarenontoxic.Thenon-amyloidogenicα-secretase
pathway occurs in over 90% of humans, and these individuals generally do not develop dementia. In the amyloidogenic pathway (right),
cleavage occurs by β-secretase at the beginning of the amyloid-beta domain and generates a soluble N-terminus fragment (sAPPβ)a n d
amyloidogenic C-terminal fragment of 99 residues (C99). This C-terminal fragment is further cleaved by γ-secretase and generates amyloid-
beta. The amyloidogenic pathway occurs in approximately 10% of total humans, and these individuals might develop dementia and AD.
[49]. Moreover, amyloid-beta interacts with mitochondrial
matrix components inducing an improper mitochondrial
complex function leads to a decreased mitochondrial mem-
brane potential of the organelle [50] and impairing ATP
formation [51].
In APP processing, monomeric amyloid-beta forms
oligomers in synaptic terminals. Oligomeric amyloid-beta is
hypothesized to enter in the mitochondria by penetrating
the membrane because amyloid-beta is enriched at synaptic
terminals [52]. In support of the hypothesis that APP
and amyloid-beta enter mitochondria, several studies have
found APP and its derivatives (monomeric and oligomeric
forms of amyloid-beta) in mitochondrial membranes [53,
54]. Amyloid-beta normally interact with the mitochondrial
matrix protein, amyloid-beta-binding alcohol dehydroge-
nase (ABAD), leading to mitochondrial dysfunction [9].
Caspersen et al. [41] showed amyloid-beta in mitochondria
from postmortem brain specimens of AD patients and an
accumulation of amyloid-beta in the brain mitochondria
from APP mice. With digitonin fractionation analysis of
isolated mitochondria from APP mice revealed amyloid-beta
in outer and inner mitochondrial membranes and matrix
and that mitochondrial amyloid-beta decreases cytochrome
oxidase activity and increases free radical production and
carbonyl proteins [28].
Further, in the amyloid interactions in mitochondrial
proteins, two more studies found that APP interacts directly
with mitochondrial proteins. It was demonstrated that
mitochondrial ATP synthase subunit is a binding partner
of the extracellular domain of APP and amyloid-beta [50].
Transfection of APP-deﬁcient neuroblastoma cells with APP
resulted in increased surface localization of the ATP syn-
thase a-subunit and in extracellular APP and amyloid-beta
inhibiting the extracellular generation of ATP. In another
study, the authors found that nonglycosylated full-length
and C-terminal-truncated APP accumulates in the protein
import channels of mitochondria of human AD brains but
not in age-matched controls [27]. The accumulation of APP
across mitochondrial import channels inhibited the entry
of nuclear-encoded cytochrome c-oxidase subunits IV and
Vb proteins and was associated with decreased cytochrome
oxidase and increased free radical production.
5. Mitochondrial DNA (mtDNA) Changes inAD
It is well documented that mtDNA changes are responsible
for aging phenotypes [55–57]. For example, many tissues
from aged individuals have a lower respiratory function
compared with those from younger individuals. It has been
hypothesized that ongoing oxidative damage to mtDNA may
be the underlying mechanism for cellular senescence [58].
Since mtDNA repair mechanisms are limited and because
mtDNA is situated in close proximity to the site of ROS
production, mtDNA is more vulnerable to oxidative damage
than nuclear DNA [59]. With age, oxidation of mtDNA
increases compared to nuclear DNA leading to an age-
dependent accumulation of mtDNA mutations [60].
Point mutations and deletions in mtDNA are highly
prevalent in aged cells, and there is evidence that 8-hydroxy-
2- deoxyguanosine (damaged DNA) is more prevalent inJournal of Aging Research 5
aged tissues [55]. Further, mice carrying an mtDNA muta-
tion (in the DNA polymerase-g gene) showed features of
aging and reduced lifespan, suggesting that mtDNA changes
are crucial for aging phenotypes [56].
Defects in mtDNA have not only been found in elderly
personswithoutADbutalsoinADpatients[61,62]andhave
been associated with decreased cytochrome oxidase activity
in non-AD aging and aging AD brains. One recent study
found that somatic mtDNA control region mutations are
elevated in AD patients [63]. These mutations would lead to
an overall reduction in mtDNA copy number which would
resultinadecreaseinoxidativephosphorylation.Inaddition,
a mutation that aﬀects L-strand transcription was also dis-
covered. This mutation inhibits complex I respiration which
leads to increased ROS production, decreased membrane
potential, and subsequent calcium deregulation. The eﬀects
of these mutations may lead to opening of the mitochondrial
permeability transition pore and subsequent neuronal death.
Increased ROS levels act at multiple levels to impair
mitochondrial function: they induce mtDNA mutations
[64] that consequently negatively inﬂuence mitochondrial
function [65], enhance amyloid-beta production by guiding
APP cleavage pathway toward the amyloidogenesis [66],
increase lipid peroxidation [67, 68], activate mitophagy,
leading to a reduced mitochondrial number [36], and
augment tau hyperphosphorylation and NFT formation
impairing organelle traﬃcking and neuronal function ﬁnally
leading to apoptosis.
Using quantitative RT-PCR techniques, it was measured
mRNA expression of 11 mitochondrial-encoded genes in
patients with early AD and with deﬁnite AD, as well as
in age-matched control subjects. This interesting analysis
revealed a downregulation of mitochondrial genes in com-
plex I of OXPHOS (oxidative phosphorylation) in brain
of AD patients. Complex I showed a down regulation of
mitochondrial genes, whereas complexes III and IV showed
increased mRNA expressions in these AD brains, suggesting
a great demand on energy production [35]. In a previous
paragraph, we reported a decrease of cytochrome oxidase
in the mitochondria from platelets, ﬁbroblasts, and brains
of AD patients. To compensate for the loss of cytochrome
oxidase, mitochondrial-encoded genes might be activated
in the surviving brain neurons of AD, for those patients
this chain of events has been interpreted as a compensatory
response [26].
6. Mitochondriaand SynapticDamage inAD
Synaptic degeneration is an early pathological feature in AD
and is closely correlated to impaired cognitive function and
memory loss. Recent studies suggest that involvement of
amyloid-beta peptide in synaptic mitochondrial alteration
underlies these synaptic lesions. Based on recent ﬁndings in
human AD subjects, AD animal models, and AD cellular
models, synaptic mitochondria undergo multiple malfunc-
tionsincludingamyloid-betaaccumulation,increasedoxida-
tive stress, decreased respiration, and compromised calcium
handling capacity, all of which occur earlier than changes
seen in nonsynaptic mitochondria prior to predominant
AD pathology. Of note, the impact of amyloid-beta on
mitochondrial motility and dynamics exacerbates synaptic
mitochondrial alterations.
Mitochondrial number is indeed very high in neurons,
and mitochondria are especially enriched in synapses. Due
to the limited glycolytic capacity of neurons, these cells
are highly dependent on mitochondria function for energy
production. Thus, the importance of synaptic mitochondria
in supporting synapses and the high vulnerability of synaptic
mitochondria toamyloid-beta make thema promising target
of new therapeutic strategy for AD.
Synapticmitochondriaaresynthesizedinneuronalsoma;
they are then transported to dendrites and axones, are dis-
tributed abundantly around synapses where mitochondria
modulate calcium balance, and actively provide energy to
fuel the synaptic function [69, 70]. If mitochondria localized
in the cell body are damaged or are otherwise degraded, such
as by aging or by amyloid-beta, these defective mitochondria
might be transported to synaptic terminals by natural
mitochondrial traﬃcking, where they produce low levels of
ATP owing to their degradation. Synaptic mitochondria thus
undergo constant activation to maintain synaptic function.
Defects in synaptic mitochondria obviously compromise
synaptic function being very vulnerable to accumulative
damages.
Mitochondrial dysfunction and synaptic damage are
early pathological features of AD. Gillardon et al. found am-
yloid-beta oligomers in synaptosomal mitochondrial frac-
tions and decreased energy metabolism in AD transgenic
mice [71]. Abnormalities of mitochondrial function, includ-
ing decreased mitochondrial respiration, ROS generation,
and hypometabolism, occur in the AD brain [39, 72]a n d
in brains of AD mouse models [73, 74]. Amyloid-beta
accumulation in the synapses directly disturbs mitochon-
drial function, causing oxidative stress, decreased ATP, and
increased Ca2+ inﬂux [9, 75]. Furthermore, the interaction
of mitochondrial amyloid-beta with its binding proteins,
such as ABAD and CypD [9, 75], exacerbates amyloid-beta-
induced mitochondria and neuronal stress and malfunction.
Further, it was recently showed that amyloid-beta
impaired synaptic mitochondrial distribution, axonal mito-
chondrial mobility, and increased axonal mitochondrial
fragmentation. Interestingly, anterograde movements were
more susceptible to amyloid-beta insult. These promising
ﬁndings are in agreement with those of recent studies indi-
cating that amyloid-beta causes rapid and severe impairment
of mitochondrial transport [47] and alters mitochondrial
dynamics [76].
Synaptic terminals are sites of high energy demand
and require high levels of cellular ATP for neurotrans-
mitter exocytosis and the potentiation of neurotransmitter
release. These studies suggest that in an amyloid-beta-
rich environment, overt mitochondrial dysfunction occurs
and that mitochondria provide a direct site for amyloid-
beta-mediated cellular perturbation, causing synaptic mito-
chondrial dysfunction in AD. However, it is not yet
known whether amyloid-beta accumulates predominantly in
synaptic mitochondria and whether synaptic mitochondria6 Journal of Aging Research
enriched for amyloid-beta are more vulnerable, although it
is well known that the increase in oxidative damage exhibited
by synaptic mitochondria might aﬀect neurotransmission
and synaptic damage and loss and might be ultimately
responsible for cognitive decline in AD patients.
In view of the critical role of synaptic mitochondria in
energy production, synaptic calcium buﬀering, and regu-
lation of synaptic function, impaired movement to and se-
questration of mitochondria at synapses by amyloid-beta
could be a mechanism of the pathogenesis at the distal
synapses, together with early changes in synaptic mitochon-
drial function.
7. Mitochondrial Dysfunction in
Choroid Plexus
In AD is very well documented the intracellular deposits of
amyloid-beta in the brain parenchyma; however, amyloid-
beta also accumulates in choroid plexus epithelial cells [77]
and in cerebrovascular walls, where it induces blood-brain
barrier disruption [78]. Several studies have shown that
amyloid-beta alters transmembrane and cytoplasmic tight
junction proteins in brain microvessel endothelial cells and
choroid plexus, which ultimately leads to disruption in the
integrity of the blood-brain barrier [79, 80].
Abnormal patterns of mitochondrial stress protein
expression are found in the choroid plexus and BBB of AD
subjects. There was a trend towards increased expression of
HSP60, a mitochondrial stress protein, compatible with mi-
tochondrial pathology recently documented in choroid
plexusofAD[81].Itwasrecentlydescribedinchoroidplexus
homogenates from 27 cases with AD-related pathology
in diﬀerent stages (stages I/0, III-IV/0-B and V-VI/B-C)
increased carboxyethyl-lysine (CEL) and carboxymethyl-
lysine (CML) expression in AD cases stages IVB and V-
VI/B-C when compared to controls and cases with AD-
related pathology. Interestingly, the authors suggest that
other factors in addition to local ﬁbrillar amyloid-beta were
associated with oxidative damage in the choroid plexus.
Though two-dimensional gel electrophoresis in combination
with mass spectrometry identiﬁed other proteins as targets
of increased oxidative damage in AD (tyrosine 3/trypto-
phan 5-monooxygenase activation protein, zeta polypeptide,
tropomyosin 3 isoform, and apolipoprotein A-II) [82].
Recent results from our laboratory have suggested
direct relationship between amyloid-beta accumulation at
the choroid plexus epithelium and the development of
functional and structural dysfunctions [77, 83]. In addition,
we demonstrated the existence of a link between amyloid-
beta-inducedchoroidplexuscelldeath,increasedproduction
of nitric oxide (NO), and mitochondrial dysfunction in the
choroid plexus of patients with AD and APP/PS1 mice [83].
In AD patients and APP/Ps mice, we found an alteration
induced by amyloid-beta of the enzyme activity of the
respiratory chain complex IV in the choroid plexus epithelial
cells [84].Accumulationofamyloid-betapeptidesisacritical
event in the pathology of AD, because they induce multiple
neurotoxic eﬀects, including mitochondrial dysfunction.
Basedontheseresults,weconsideredareductionofamyloid-
beta with gelsolin such as primary therapeutic target [85].
Gelsolin is an amyloid-beta binding protein that inhibits
apoptosis, although the underlying mechanism is unclear.
Weobservedthatgelsolinreducesbrainamyloid-betaburden
in the APP/Ps1mice, accompanied byan inhibition of nitric-
oxide production and cell death, not only in the choroid
plexus but also in the cerebral cortex. Gelsolin levels restored
the impaired mitochondrial activity, resulting in the increase
of cytochrome c-oxidase activity [84].
Additionally, these result demonstrated that gelsolin
plays an important role in decreasing amyloid-beta-induced
cytotoxicity by inhibiting nitric oxide production and apop-
totic mitochondrial changes. All these promising ﬁndings
make gelsolin an appealing tool for the prophylactic treat-
ment of AD.
8. Conclusions
Basedonﬁndingsfrominvitroandinvivostudies,ithasbeen
proposed that amyloid-beta has a signiﬁcant role in synaptic
dysfunction and cognitive decline in AD patients. Among
other facts, amyloid-beta accumulates at synaptic terminals
and enters the mitochondria, especially in the synaptic
mitochondria. Mitochondria have been implicated in the
neurodegenerative diseases and the onset and progression of
age-associated diseases since decades. Mitochondria are the
major source of energy for the brain [86]. The accumulation
of mtDNA changes might increase ROS production and
reduce mitochondrial ATP in an age-dependent manner.
Recent studies of neurons from postmortem AD brain
specimens and from transgenic AD mouse brain specimens
suggest that oxidative damage induces amyloid-beta produc-
tion.
Studies of postmortem brains from AD patients and
transgenic mouse models of AD suggest that oxidative
damage, induced by amyloid-beta, is associated with mito-
chondria early in AD progression. Amyloid-beta present
within mitochondria may provide a direct link between
mitochondrial dysfunction in AD and pathogenic amyloid-
beta. Amyloid-beta associated with mitochondria may be
deposited at several locations, and yet nobody has known
if amyloid-beta enters only in presynaptic mitochondria,
postsynaptic mitochondria, or both. Interestingly, amyloid-
beta is not present exclusively on the outer mitochon-
drial membrane and also might be present at that site
to inﬂuence the interaction of multiple cytosolic proteins
(including those of the bcl2 family) with mitochondria,
as well as aﬀecting the receptor binding of cargo targeted
for import into the organelle. Amyloid-beta and APP are
reported to localize to mitochondrial membranes, block
the transport of nuclear-encoded mitochondrial proteins to
mitochondria, interact with mitochondrial proteins, disrupt
electron transport chain activities, increase ROS production,
cause mitochondrial damage, and prevent neurons from
functioning normally.
The mechanisms of amyloid-beta and APP transport
into mitochondrial membranes are unclear. Amyloid-betaJournal of Aging Research 7
accumulates at synaptic terminals and impairs synaptic
function and also enters synaptic mitochondria and causes
damage. Mitochondrial damage is expected to be greater
in synaptic mitochondria than in cell body mitochondria.
The damaged, synaptic mitochondria might not satisfy the
high energy demands required at synapses, which might lead
to impaired neurotransmission and, ultimately, to cognitive
failure. Based on these concepts, therapies targeting basic
mitochondrial processes, such as energy metabolism or
free radical generation, or speciﬁc interactions of disease-
related proteins with mitochondria, hold great promise and
future. In AD, tremendous progress has been made in
developing therapeutic strategies to decrease amyloid-beta
production and toxicity. However, further research is needed
to develop molecules that target intact amyloid-beta in brain
neurons aﬀected by AD. Further research is also needed to
test the eﬃcacies of mitochondrially targeted antioxidants
in AD mouse models. Future experiments that focus on
the functional association of mitochondria with APP and
amyloid-beta might be useful for identifying mitochondrial
drug targets.
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